After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Earlier, Yahoo Finance discussed this stock as it revealed Gilead Sciences with Emma’s Story: Self-Advocacy in Breast Cancer.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
GILD belongs to the Healthcare sector of the NASDAQ while operating in the Drug Manufacturers – General industry. At the end of the last regular session, the stock closed at $87.29 and fluctuated between $87.86 as its day high and $86.10 as its day low. The current market capitalization of Gilead Sciences, Inc. is $108.77B. A total of 6.4 million shares were traded on the day, compared to an average of 6.43M shares.
Insider Activity
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, GILD has seen 2 BUY and 2 SELL insider trades, representing the acquisition of 2,426 and the disposition of 1,047 shares. Over the last 12 months, there were 49 BUYs and 36 SELLs from insiders. Insiders purchased 586,538 shares during that period but sold 214,404.
In the most recent transaction, Dickinson Andrew D sold 5,000 shares of GILD for 85.78 per share on Jan 16. After the transaction, the Chief Financial Officer now owns 101,534 company shares. In a previous transaction on Jan 09, Mercier Johanna sold 8,242 shares at 85.23 per share. GILD shares that Chief Commercial Officer owns now total 82,729.
Among the insiders who sold shares, Dickinson Andrew D disposed of 5,000 shares on Oct 17 at a per-share price of $80.00. This resulted in the Chief Financial Officer holding 104,003 shares of GILD after the transaction. In another insider transaction, Parsey Merdad sold 1,501 shares at $76.99 per share on Sep 12. Company shares held by the Chief Medical Officer now total 70,130.
Dividend
Paying dividends generates immediate cash flow for investors and indicates a positive outlook for the company. Gilead Sciences, Inc. pays an annual dividend of $3.08, resulting in a dividend yield of 3.53%, and it has a price to earnings (P/E) ratio of 18.72. GILD’s most recent ex-dividend date was 12/14/2023 when it declared a $0.75 quarterly dividend that was paid in cash on 12/28/2023. Previously, the company paid the dividend on 9/28/2023 with an ex-dividend date of 9/14/2023. The GILD stock dividend was $0.75 per share in cash.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for GILD in the last 3 months, the mean price target is $89.57 with high estimates of $116.00 and low estimates of $69.00. In terms of 52-week highs and lows, GILD has a high of $87.82 and a low of $72.87.
As of this writing, GILD has an earnings estimate of $1.78 per share for the current quarter. EPS was calculated based on a consensus of 23 estimates, with a high estimate of $2.04 per share and a lower estimate of $1.59. The company reported an EPS of $1.34 in the last quarter, which was -18.30% lower than expectations of $1.64.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. GILD’s latest balance sheet shows that the firm has $6.52B in Cash & Short Term Investments as of fiscal 2021. There were $26.70B in debt and $11.61B in liabilities at the time. Its Book Value Per Share was $17.89, while its Total Shareholder’s Equity was $21.06B.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for GILD is Buy with a score of 4.05.
